Amyloid-β (25-35) Modulates the Expression of GirK and KCNQ Channel Genes in the Hippocampus

Jennifer Mayordomo-Cava¹, Javier Yajeya², Juan D. Navarro-López¹*, Lydia Jiménez-Díaz¹*

¹ University of Castilla-La Mancha, Neurophysiology & Behavior Lab, CRIB, School of Medicine of Ciudad Real, Ciudad Real, Spain, ² University of Salamanca, Department of Physiology & Pharmacology, Salamanca, Spain

* Lydia.Jimenez@uclm.es (LJD); Juan.Navarro@uclm.es (JDNL)

Abstract

During early stages of Alzheimer’s disease (AD), synaptic dysfunction induced by toxic amyloid-β (Aβ) is present before the accumulation of histopathological hallmarks of the disease. This scenario produces impaired functioning of neuronal networks, altered patterns of synchronous activity and severe functional deficits mainly due to hyperexcitability of hippocampal networks. The molecular mechanisms underlying these alterations remain unclear but functional evidence, shown by our laboratory and others, points to the involvement of receptors/channels which modulate neuronal excitability, playing a pivotal role in early Aβ-induced AD pathogenesis. In particular, two potassium channels that control neuronal excitability, G protein-coupled activated inwardly-rectifying potassium channel (GirK), and voltage-gated K channel (KCNQ), have been recently linked to Aβ pathophysiology in the hippocampus. Specifically, by using Aβ25-35, we previously found that GirK conductance is greatly decreased in the hippocampus, and similar effects have also been reported on KCNQ conductance. Thus, in the present study, our goal was to determine the effect of Aβ on the transcriptional expression pattern of 17 genes encoding neurotransmitter receptors and associated channels which maintain excitatory-inhibitory neurotransmission balance in hippocampal circuits, with special focus in potassium channels. For this purpose, we designed a systematic and reliable procedure to analyze mRNA expression by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) in hippocampal rat slices incubated with Aβ25-35. We found that: 1) Aβ down-regulated mRNA expression of ionotropic GluN1 and metabotropic mGlu1 glutamate receptor subunits as previously reported in other AD models; 2) Aβ also reduced gene expression levels of GirK2, 3, and 4 subunits, but did not change expression levels of its associated GABAB and M1 receptors, respectively. Our results provide evidence that Aβ can modulate the expression of these channels which could affect the hippocampal activity balance underlying learning and memory processes impaired in AD.
Introduction

Lastest findings support the emerging concept that the effects of Amyloid-β (Aβ) in Alzheimer disease (AD) initially center on subtle alteration of synaptic function and, thus, precede synapse loss, plaque accumulation, the formation of tangles and neurodegeneration [1]. In this scenario, Aβ would affect neuronal activity at the molecular, synaptic or network level acting on a particular receptor/channel and inducing an imbalance between excitatory and inhibitory neurotransmission systems in relevant areas for learning and memory processes that might underlie the synaptic dysfunction found before the neurological AD deficits [2–4].

In AD, the hippocampus is one of the brain regions firstly affected. This region is a highly organized structure playing a pivotal role in learning and memory processes by the accurate balance between excitatory and inhibitory systems [5]. Memory deficits and disorientation are the first symptoms of AD [6,7] which brought up the hypothesis that hippocampal synaptic transmission and plasticity may be impaired in experimental models of the disease [2,8–11]. Humans with AD, particularly early-onset AD and familial AD, have an increased incidence of convulsive seizures [12]. Furthermore, AD transgenic models, as human amyloid precursor protein (hAPP) transgenic mice, present epileptiform activity and the downstream consequences of such aberrant hippocampal network synchronization and cognitive impairments [13]. Therefore, synaptic depression and aberrant network activity coexist in AD and seem to be mechanistically related [1,3]. It has also been reported that restoring hippocampal inhibitory cells activity and inhibitory synaptic currents is able to reduce premature mortality, network hypersynchrony, and memory deficits in hAPP mice [14]. Thus, experimental manipulations that prevent network hyperexcitability would provide key insights into the pathogenesis of AD and open new therapeutic approaches.

In this regard, several mechanisms of loss-of-function of sodium [14] or potassium [15–17] channels (Kv4.2, KCNQ and GIRK channels), which control neuronal excitability, have been recently proposed to contribute to the alteration in AD hippocampal inhibitory neurotransmission, and to the subsequent network hyperactivity and hypersynchrony [18]. In particular, we have recently showed for the first time that Aβ25–35 decreases GABAB currents in CA3 pyramidal neurons, which likely occurs by decreasing GIRK channels conductance, and leads to hippocampal hiperexcitability in vitro [4,16]. However, the molecular mechanisms that could underlie the above Aβ-induced functional changes, i.e, synaptic dysfunction and hippocampal neurotransmission imbalance, remain mostly unrevealed, particularly at the transcriptional level [2,4].

Therefore, we have studied the transcriptional expression of neurotransmitter receptors and associated channel genes involved in neuronal excitability control, that may more likely be targeted by Aβ [4]. We developed and validated a highly sensitive reverse transcription-qPCR (RT-qPCR) assay to quantify relative mRNA levels in rat hippocampal slices incubated for long periods (up to two hours) with Aβ25–35 (the same preparation used in our previous electrophysiological studies [16]). We standardized RNA quality control to check RNA integrity maintenance in hippocampal slices and also calculated unbiased stability values of putative valid reference genes to achieve accurate and reproducible mRNA quantification in the hippocampal slice preparation. Specifically, we analyzed the modulation by Aβ of mRNA levels of 17 receptors/ channels genes that participate in excitatory and inhibitory neurotransmission involving glutamatergic, GABAergic and muscarinic systems in the rat hippocampus [4]. For the study of the glutamatergic system, NMDA, AMPA and Group I of metabotropic receptors were selected while for the cholinergic system, M1 receptor and subunits of its effector, KCNQ channel were analyzed. Finally, in the GABAergic system, subunits of GABAq receptor and its effector, GIRK channel, were studied [4]. Since it has been reported that Aβ early soluble forms anomalously increase activity-regulated cytoskeleton-associated protein (Arc) levels in AD.
patients and animal models [19], we also analyzed its mRNA expression as a positive control to validate our results.

In summary, our data indicate that Aβ modifies the mRNA expression levels of GluN1 and mGlu1 glutamatergic subunits as expected by previous reports [20,21], but also decreases the mRNA expression levels of different subunits of two potassium channels, *Girk2* and *Kcnq2-3*, that control neuronal excitability and have been recently linked to hippocampal AD pathophysiology. We suggest that these impairments at the transcriptional level could contribute to the final excitatory-inhibitory hippocampal neurotransmission imbalance that causes aberrant network activity and early cognitive impairment found in AD models [1,3,4].

**Methods**

**Animals**

Experiments were carried out on Wistar rats (50–100 g; P23-33) obtained from an authorized distributor (Criffa Laboratories, France). All animal procedures were reviewed and approved by the Ethical Committee for Use of Laboratory Animals of the University of Castilla-La Mancha, and followed the European Communities Council guidelines (86/609/EEC).

**Preparation of slices**

Animals were deeply anesthetized with halothane gas and decapitated. The brain was excised and rapidly immersed in modified oxygenated ice-cold (4–6°C) artificial cerebrospinal fluid (ACSF) containing: (in mM) 234 Sucrose, 4.7 KCl, 2.5 CaCl$_2$, 1.2 MgCl$_2$, 25 NaHCO$_3$, 1.2 NaH$_2$PO$_4$, and 11 glucose. Horizontal hippocampal slices (350 μm-thick) were cut in cold oxygenated modified ACSF solution using a vibratome (Microm 7000smz-2, Campden Instruments Ltd, UK). Hippocampal slices from each single hemisphere were obtained using a dissecting microscope (Fig 1A), placed in an incubation chamber with ACSF containing NaCl (117 mM) replacing sucrose and maintained in a carbogen (95%CO$_2$/5%O$_2$) saturated atmosphere at room temperature through the incubation time, as we previously described [16,22,23].

**Preparation of Aβ$_{25–35}$ peptide solutions**

It has been proposed that Aβ$_{25–35}$ constitutes the biologically active fragment of Aβ [24], and has been shown to induce major neuropathological signs related to early stages of AD in rats [25]. In addition, Aβ$_{25–35}$ is reported to be more soluble and presents toxic effects more rapidly than the parent peptide Aβ$_{1–42}$ [26] and has widely been used as a very useful tool to explore acutely the pathophysiological events related with neuronal dysfunction induced by soluble Aβ forms [16,22,27–29]. In addition, the main advantage for present work is that Aβ$_{25–35}$ does not form ion-permeable pores in neuronal membrane but acts mainly on neurotransmission [16,27,30,31].

Therefore, Aβ$_{25–35}$ peptide was prepared as previously described by our laboratory [16,22,29]. Briefly, the peptide was dissolved to 1 mM in bidistilled water and stored in aliquots at -20°C. Then aliquots were diluted in ACSF to required concentration of 1 μM and incubated for 24 hours at 37°C before experiments were performed [16]. Final concentration of 1 μM was chosen based on our previous functional results obtained with the same concentration in 350 μm-thick hippocampal, amygdalar and septal slices [16,22,29].

**Experimental design**

Hippocampal slices were incubated at room temperature in two different conditions, 1) ACSF or 2) ACSF enriched with Aβ$_{25–35}$ (Sigma, Poole, UK), during different time periods (0, 30, 120 minutes) (Fig 1B). Time points for gene expression analysis where chosen based on our
previous in vitro results obtained for Aβ25–35 in the same experimental preparation [16]. Our previous data showed Aβ25–35 synaptic activity disruption as early as 20 min after perfusion of the peptide that lasted up to 2 h. In addition, maximum activity-dependent gene expression changes have been reported to take place within the time window of 0.5-2h [32,33]. Therefore
30 and 120 min were selected in order to correlate synaptic dysfunction induced by Aβ with changes in mRNA expression levels.

Finally, the slices were collected after incubation and frozen at −80°C at each time point until further processing.

**RNA extraction, RNA quality and integrity, and reverse transcription of mRNA**

Total RNA was extracted from single homogenized hippocampal slices using Trizol (Invitrogen, Paisley, UK) and total RNA was purified using Rneasy Mini Kit (Qiagen, Crawley, UK). RNA samples were treated with DNase I (Qiagen, Crawley, UK) according to the manufacturer’s protocol. For all samples, RNA quantification was routinely assessed on a Nanodrop 2000c spectrophotometer (Thermo Scientific, Wilmington, USA). The quality and integrity of total RNA was analyzed by using the RNA Quality Indicator number (RQI), which is calculated from electropherograms obtained from an automated electrophoresis system (Experion System, Bio-Rad, USA). The electropherogram shows the RNA profile of ribosomal RNA degradation [34], according to the premise that over time RNA would accumulate as small degraded RNA with low molecular weight (Fig 1C). The RQI allowed us to classify the quality of the hippocampal samples from 1–10 (Table 1). The criterion for selection of the RNA samples used for subsequent cDNA synthesis and gene expression analysis was RQI ≥ 7.5 [34].

cDNA synthesis was performed by reverse transcription (RT). 0.198 μg of total RNA for each sample were reversed transcribed using random nonamers 2 μM (Sigma, Poole, UK), oligo(dT)20 primers 1 μM (Promega, Wisconsin, US), dNTPmix 0.5 μM, (Promega, Wisconsin, US) in a RT mix volume of 13 μl per sample. Then we performed a “two step” amplification cycle: 1) RT mix was incubated at 65°C for 5 min in a T-Professional Thermocycler (Biometra, Gottingen, Germany) for primers annealing and 2) RT was performed adding to RT mix Buffer First-Strand 5X (Invitrogen, Paisley, UK), DTT 0.1 M ribonuclease Inhibitor 40 unit/μl (Promega, Wisconsin, US) and Superscript TM III RT (Invitrogen, Paisley, UK) in a final volume of 20 μl per sample. Then, RT mix was incubated at 25°C for 5 min, 50°C for 50 min and 70°C for 15 min.

**Quantitative polymerase chain reaction (qPCR)**

qPCR reactions were performed with equal amount of cDNA template, TaqMan fast Universal Master Mix (2x) without AmpErase UNG and TaqMan Gene Expression Assays (20X) (Applied Biosystems, Carlsbad, US) for the 18 genes of interest (see S1 Table) according to the manufacturer’s protocol. The following thermal cycling specifications were performed on the ABI 7900 Fast Real-Time PCR system (Applied Biosystems, Carlsbad, US): one cycle at 95°C for 20 s, 40 cycles at 95°C for 3 s and one cycle 30 s at 60°C. Unless otherwise stated, all qPCR reactions were performed with 5 biological samples and each sample had a technical duplicate.

**Table 1. RNA integrity and quality.** RNA quality indicator (RQI) for hippocampal slices and percentage of samples for each RQI value range.

| RQI          | %     | RNA Quality    |
|--------------|-------|----------------|
| RQI ≤ 6      | 2.5   | Very degraded  |
| 6 < RQI ≤ 7.5| 15    | Lightly degraded|
| 7.5 < RQI ≤ 8.5 | 32.5 | Good quality   |
| 8.5 < RQI ≤ 10 | 50   | High quality   |

doi:10.1371/journal.pone.0134385.t001
Negative control RT samples (Non RT; samples without transcriptase for detection of genomic DNA contamination) and Non template controls, NTC-RT; samples that contained only RNasa/DNase free water, for detection of primers dimmers and contamination) were always included, as well as samples without cDNA template, NTC-qPCR (contained only RNasa/ DNase free water for detection of probe’s degradation in qPCR reaction). No product was synthesized in negative controls, indicating that RT and qPCRs reagents were not contaminated. qPCR experiments were performed in accordance with MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines [35].

For relative mRNA quantification Cq values (Cq, standard name for threshold cycle or crossing point value according to the Real-Time PCR Data Markup Language, RDML guidelines, [36]) were calculated in each sample set for reference and target genes. The expression of each target gene relative to a normalizing factor (a reference gene that was chosen accordingly to its stability; see section below) was calculated using the $2^{-\Delta\Delta Cq}$ method [37,38] as described by the manufacturer (Applied Biosystems: User Bulletin 2). Changes in gene expression through the time course were reported as percent changes relative to basal control expression at time zero (t = 0 min, i.e. before Aβ was added to the incubation media).

Reference gene selection

In order to compare the relative expression levels of Aβ-targeted genes following a standardized and reliable procedure, data were normalized based on the most stable reference gene in our experimental design.

As selection of suitable reference genes is critical for data normalization and interpretation, two steps were performed to choose the most stable reference gen [39]. First, the stability of three putative commonly used reference genes [40], Actb (β-actin), Gapdh (Glyceraldehyde 3-phosphate dehydrogenase), and Ppia (Peptidylprolyl isomerase A) was analyzed. Relative mRNA levels of reference genes were studied for all experimental conditions. Cq value for each reference gene was normalized to Cq mean value for t = 0, and mRNA level for these samples was considered 100%. The analysis revealed that mRNA levels of the three candidate reference genes were steady as expression levels of the three genes were no significantly affected by time incubation (Actb: F(2,19) = 0.387, p = 0.684; Gapdh: F(2,19) = 0.643, p = 0.537; Ppia: F(2,18) = 1.921, p = 0.175), nor by Aβ incubation (Actb: F(1,19) = 0.432, p = 0.519; Gapdh: F(1,19) = 0.157, p = 0.696; Ppia: F(1,19) = 2.928, p = 0.104), suggesting that any of them would be appropriate as reference gene for our experimental conditions.

Second, to determine the most stably expressed reference gene among the different candidates, the raw Cq values obtained for each sample for the candidate endogenous control genes were processed by two different algorithms: NormFinder v0.953 [41] and BestKeeper v1 [42] applications. These bioinformatics packages calculate a stability value, whereas a lower value means a higher stability in gene expression. The genes were ranked according to these obtained gene stability values and that with the lowest value chosen for data normalization.

Using this two-step approach that includes analysis by bioinformatics algorithms of expression stability of plausible reference genes allowed us to select the most stable gene based on an objective value and exemplify the importance of selecting a particular reference gene among different candidates to properly standardize the analysis and quantify relative mRNA levels.

Statistical analysis

Results were expressed as mean ± standard error of the mean (SEM). All calculations were performed using SPSS version 20 software (SPSS Inc., Chicago, IL). Comparisons of mRNA relative expression or of RNA integrity were made using two way ANOVA and followed by
Bonferroni post hoc test when the distribution of the variables was normal. If the Levene’s test for normal distribution was significant then data were normalized by logarithmic (log) transformation. When the variables did not show normal distribution after transformation, comparisons were made using non-parametric tests. Significance level was set at $p \leq 0.05$.

**Results**

**Standardization of the analysis of mRNA expression patterns in hippocampal slices**

In order to standardize our RT-qPCR study, unbiased values were calculated to determine both: i) integrity and quality of the RNA extracted from hippocampal slices and ii) stability of reference genes in our experimental design.

**RNA integrity and quality**

Total RNA was extracted and purified from hippocampal slices ($n = 44$). RNA integrity was analyzed for all samples using RQI value, which was calculated based on the electropherogram areas that corresponded to the regions of 28S, 18S and pre-18S ribosomal RNA (Fig 1C). Hippocampal total RNA quality was also checked by virtual gel images (Fig 1C, right column). As shown in Table 1, RQI values were divided into four groups according to our pre-established criterion. Data showed that more than 80% of the samples presented total RNA of highest quality (Table 1), confirming that the model would be appropriated to study the effects induced by Aβ on the RNA obtained from the slice. No significant differences in RNA integrity were found neither during Aβ incubation ($F(1,35) = 0.206; p = 0.652$) nor time ($F(2,35) = 0.826; p = 0.446$).

**Selection of the most stable reference gene**

As indicated in the methods section, stability of the possible reference genes ($Ppia$, $Gapdh$ y $Actb$) in our experimental conditions was first evaluated. Among suitable candidates confirmed by this first analysis, the most stably expressed reference gene (i.e. the one with lowest variation and highest stability across biological samples) was finally selected for analysis of relative expression levels of target genes after Aβ treatment in hippocampal slices. mRNA expression levels of the three proposed genes ($Ppia$, $Gapdh$ y $Actb$) were found to be steady (see methods section) so they were all considered as suitable candidates for later bioinformatic analysis of stability. To select the most stable reference gene across the tested ACSF and Aβ conditions, the expression stabilities of the 3 candidates, $Ppia$, $Gapdh$ y $Actb$, were analyzed with two different software tools, NormFinder Program [41] and BestKeeper Program [42]. After data were analyzed and genes ranked by both programs, the lowest rank represented the most stably expressed reference gene, whereas the highest rank represented the least stably expressed reference gene. Across the three candidates, $Ppia$ was identified as the most stably expressed reference gene by both programs (Fig 1D) and used for further analysis.

**Aβ effects on hippocampal gene expression**

In order to achieve the main aim of the present study, i.e to investigate the effect of Aβ on hippocampal expression of genes related to glutamatergic, cholinergic and/or GABAergic neurotransmission, we studied the expression pattern of 17 subunits of receptors/ channels than control neuronal excitability, using $Ppia$ as reference gene. As stated above, mRNA expression of $Arc$ was analyzed as positive control. Soluble Aβ has been shown to induce Arc expression itself [19,43] and Arc overexpression has been linked to dysfunctional learning, suggesting a
molecular basis for the specific loss of memory function in early AD. Accordingly, our results showed Aβ to significantly increase Arc mRNA levels at 30 and 120 minutes incubation times (Fig 2D) (F(1,9) = 5.428, p = 0.045) suggesting a role in neurophysiological alterations of our AD experimental model.

mRNA levels for ionotropic NMDA and AMPA receptor subunits were found unchanged except for NMDA GluN1 subunit, which was significantly decreased by Aβ (Fig 2A) after 30 min and 2 h incubation (F(1,9) = 7.242, p = 0.025).

Regarding metabotropic mGlu glutamate receptors, in our experimental conditions, Aβ induced mGlu1 mRNA levels to decrease (30 min, p = 0.037; 120 min, p = 0.034) while mGlu5 levels were not significantly modified (Fig 2A).

Aβ effects on mRNA expression of GABAB receptors and GIRK channels, second messenger effectors of GABAB-mediated neurotransmission, were also analyzed. mRNA levels of GABAB receptor subunits, GABA_B1 and GABA_B2 were not modulated by Aβ. However, the subunits of its effector, GirK channel, were altered by Aβ incubation (Fig 2B). Thus, mRNA expression levels for GirK2, GirK3, and GirK4 were found to be reduced at 30 and 120 minutes of Aβ incubation when compared to ACSF treated samples (GirK2: F(1,9) = 9.187, p = 0.014; GirK3: F(1,8) = 12.293, p = 0.008; GirK4: F(1,11) = 9.605, p = 0.010).

Relative expression of genes related to the cholinergic system were also analyzed and 30-minutes after Aβ incubation mRNA levels of muscarinic receptor subtype M1, Chmr1, did not changed. mRNA levels of KCNQ channel subunits (that ensemble to form M1 receptor effector) were more vulnerable and exhibited a down-regulation (Fig 2C; Kcnq2, p = 0.035; Kcnq3, p = 0.037). In addition, after 120-minutes Aβ incubation only induced a significant decrease of Kcnq3 subunit expression (Fig 2C, p = 0.034). Levels of Kcnq5 were not altered by Aβ.

Discussion

In the present work we studied the modulation by Aβ25–35 of gene expression of neurotransmitter receptors and associated channels which maintain excitatory-inhibitory balance in hippocampal circuits. We provided evidence of two targets down-regulated by Aβ, KCNQ [15,27] and GirK [16] channels, that participate in controlling neuronal excitability and have been recently related with AD pathogenesis by our laboratory and others. We also showed that Aβ reduced gene expression of glutamate ionotropic GluN1 and metabotropic mGlu1 receptor subunits. Both potassium conductances have previously been shown to be decreased by Aβ, which could contribute to the hyperexcitability and network dysfunction that underlie early stages of AD [1,2].

In the present study we used the hippocampal slice preparation that was incubated with Aβ up to 2h at room temperature. Therefore, as a crucial prerequisite for reliable qPCR conclusions we designed and standardized an unbiased method to minimize the influence of sample manipulation, time incubation and temperature in RNA integrity and data normalization in hippocampal slices. RQI number for each sample was considered and unbiased stability values for reference genes were calculated to ensure relevance, accuracy, correct interpretation, and repeatability of the assays. Therefore, our present experimental design provides reliable and consistent data concerning Aβ-modulation of key receptor/channel genes involved in hippocampal network excitability control, and lead us to consider it as a valid model for studying the acute effects induced by Aβ on gene expression profile of hippocampal rat slices.

Quality and Integrity of RNA Samples (RQI)

Only samples with RQI ≥ 7.5 were included in our study, i.e. good or high quality RNA. Our data showed that neither time nor Aβ incubation affected RNA integrity of hippocampal slices.
Fig 2. Relative expression of the main receptor and channel genes involved in excitatory and inhibitory hippocampal neurotransmission systems during Aβ incubation. Expression levels of mRNA for (A) glutamatergic (B) cholinergic and (C) GABAergic genes, at 0, 30 and 120 min after ACSF (control) or Aβ incubation, were analyzed by qPCR and normalized to Ppia, the most stably expressed reference gene in our study. Normalized 2^{-ΔCq} expression for each gene and time point is presented as percentage of gene expression at time 0 (t = 0 min) which is considered as 100% basal control expression. (A).

Relative mRNA expression levels of glutamatergic NMDA receptor subunits GluN1, GluN2A and GluN2B, AMPA receptor subunits GluA1 and GluA2, and...
Classically, RNA integrity has been evaluated using agarose gel electrophoresis, which allows studying the ratio of two bands comprising the 28S and 18S ribosomal RNA species. However this approach has been shown to be inconsistent, since relies on human interpretation of gel images [34]. In the present work, the RQI number, an algorithm based in the electropherogram areas corresponding to the regions 28S, 18S and pre-18S, was used both to evaluate RNA integrity in an unambiguous way [34] and as an objective criterion to evaluate the quality of the samples [44].

Reference genes

BestKeeper and NormFinder algorithms are novel approaches for examining potential reference genes to select the most stable housekeeping gen for a given set of conditions. Following the MIQE recommendations, in the present work 3 putative reference genes, Actb, Gapdh and Ppia, were investigated [40,45] and ranked according to their expression stability by both algorithms. In our experimental conditions, mRNA levels for the three genes were maintained, so from a classical point of view, they all could be considered suitable to be used as reference genes [46]. However, Ppia had been previously shown to be more stable than Gadph or Actb in different experimental preparations [39,47]. In agreement, in our study Ppia was selected for data normalization among the three candidate genes as both stability BestKeeper and NormFinder stability algorithms found Ppia as the most stable expressed reference gene in our experimental conditions. This result further contributes to objectify and standardize a procedure for relative gene expression analysis in hippocampal slices, and indicates that searching for appropriate reference gene or genes in any experimental design is a crucial step. Furthermore, we have shown for the first time a method to analyze the integrity of total RNA in hippocampal slices which have been used for other purposes such as electrophysiology [9]. Thus, this approach represents a powerful tool to further analyze the molecular mechanisms involved in hippocampus networking.

Aβ target genes in the hippocampus

Considering the large body of information available about its cytoarchitecture and synaptic organization, the hippocampal slice preparation is an election model suitable to be used in AD neuropharmacological studies [9]. The main advantage comes from the possibility of being used in highly controlled in vitro environments, thus preserving the cellular interactions of the brain in vivo, which allows analysis of drug effects, at the cellular and subcellular levels, on different excitatory and inhibitory neurotransmission systems [48–50].

Recent works suggest that Aβ impact transcription in several important neuronal pathways preceding neurodegeneration [51]. These impairments might underlie early Aβ-induced synaptic dysfunction and the imbalance observed in hippocampal networks which produce aberrant excitatory neuronal activity and contribute to cognitive deficits in AD models [1,8,52]. Although the precise mechanisms remain unknown, the synaptic impairments that lead to neural network hyperactivity, an early event in AD [18], is likely the mechanism involved. Along the different Aβ targets that could participate in controlling the excitability of the hippocampal networks, two potassium channels have been very recently identified: voltage-gated K
channel, Kv7 (also termed KCNQ) [15] and G protein-coupled activated inwardly-rectifying potassium channels, GirK [16]. In the present work, we found Aβ to down-regulate mRNA levels of different subunits of both type of potassium channels. We also found Aβ to reduce gene expression of glutamate ionotropic GluN1 and metabotropic mGlu1 receptor subunits.

**Glutamate receptors and Aβ.** Despite the wide evidence that Aβ affects glutamatergic neurotransmission, in our experimental conditions significant changes were only found in mRNA levels of NMDA and mGlu receptor subunits.

Glutamatergic neurotransmission through AMPA receptors has widely been involved in AD pathology with different results. It has been shown that Aβ oligomers reduce phosphorylation of GluA1 subunit leading to a decrease of surface AMPA receptors without evident alteration in mRNA transcripts [53]. Our results would be in accordance with these findings since we did not observed changes in mRNA expression levels. On the other hand, GluA2 subunit of glutamate AMPA receptors has been linked to Aβ neurotoxic mechanisms [54]. In synaptoneurosomes from prefrontal cortex, an increase in mRNA encoding GluA2 subunit has been reported to be paralleled by elevated expression of the corresponding protein in incipient AD patients [55]. However, in the latter study only one reference gene was used for data validation what might explain that we could not find such increase in our experimental conditions.

NMDA receptors activation has been extensively involved in AD-related synaptic dysfunction [56,57]. In the present study we did not find significant changes in the mRNA expression of NMDA subunits GluN2A and GluN2B while GluN1 was decreased by Aβ.

In accordance with our results, GluN1 mRNA levels were also found significantly decreased in human AD cerebral cortex [21] as well as in rat brain tissue [58]. Moreover, a study evaluating alterations in the transcriptional expression of glutamatergic receptors in late stages of sporadic AD, has shown GluN1 to be down-regulated in the hippocampus of AD patients by using qPCR and array hybridization methods [59]. It would be very interesting to know what happens in early stages of AD, when compensatory mechanisms would not have taken place yet.

Levels of GluN2B and GluN2A mRNA were decreased in susceptible regions of postmortem human AD brains, such as the hippocampus and the cortex [60]. Conversely, as in our study in rat hippocampal tissue, there is evidence that mRNA levels of and GluN2A and GluN2B subunits [61] are unchanged in AD patient’s brains. It has also been reported that Aβ regulates Fyn kinase, which has been proposed to disrupt hippocampal network activity [28]. Fyn signaling drives phosphorylation of GluN2B subunit of NMDA receptor which in turn produces altered surface expression of the receptor, dysregulation of receptor function, excitotoxicity and dendritic spine retraction [62,63]. The latter alterations are produced mainly at protein level, so they might not be detected at mRNA level. Further analysis is needed in this line.

Group I of metabotropic glutamate receptors (mGlu), mGlu1 and mGlu5, participates in the regulation of synaptic plasticity and postsynaptic glutamatergic excitability [64]. We found Aβ to decrease mRNA levels of mGlu1 but no significant differences were detected in mGlu5 mRNA expression. Similar results have been reported at the protein level in the cerebral cortex of patients with AD [20], where mGlu1 activity is down-regulated (with no changes in mGlu5) by significant decrease in its expression levels, which correlated with severity of the disease. Very recently a main role of mGluR5 as a triggering factor for the pathogenesis of AD has been proposed, mainly through the interaction of Aβ oligomers with the receptor at the protein level [65]. Further studies at the mRNA level for these receptors in hippocampal neurons are still needed.

**Potassium channels and Aβ.** Our previous studies have shown that Aβ peptide perfusion of hippocampal slices alters the septohippocampal neurotransmission through fimbria-CA3 synapse decreasing GIRK channel conductances [16]. These effects included depolarization of CA3 pyramidal neurons, input resistance increase, and decrease of the GABA_A-mediated inhibitory neurotransmission [16]. Thus, GIRK channels might play a role as a part of the
mechanisms underlying the loss of septohippocampal rhythmic state that promote failures in synaptic plasticity and memory formation observed in AD patients [4,16]. In addition to this acute effect of Aβ on GIRK function, in the present study we found that Aβ incubation also induced down-regulation of three GIRK subunits, GirK2, GirK3 and GirK4 at the mRNA level. mRNA levels of Girk2 and Girk3 were altered at 30 and 120 minutes. GIRK2 subunit is widely expressed in the brain, forms functional heterotetramers (GIRK1–GIRK2, GIRK2–GIRK3) and homotetramers (GIRK2–GIRK2) and has been implicated in various functions and pathologies [66,67], such as learning and memory, reward, motor coordination, and Down syndrome. Mutations in GIRK2 subunit have been previously reported to reduce LTP and increase LTD in hippocampus [66]. These effects are especially relevant in Down syndrome, where cerebral Aβ accumulation is greatly accelerated and leads to invariant early-onset AD neuropathology [68–70]. Therefore, our results at the mRNA level might likely imply a decrease of GIRK2 subunit at the protein level (once translated and trafficked to the membrane) and would be in accordance with the key role of GIRK2 subunit in GIRK channel function and control of hippocampal excitability.

We also found a marked down-regulation of Girk4 mRNA levels through the time course of Aβ incubation. Protein expression levels of GIRK4 are very low in most regions of the CNS when compared with the abundant expression of other GIRK subunits in the rat brain [71]. In the hippocampal formation, GIRK4 expression has been shown to be more prominent in CA3 pyramidal neurons but only moderate to low in both CA1 neurons and dentate gyrus granule cells [72,73]. However, although immunohistochemical techniques have failed to show a robust staining of GIRK4 expression in hippocampal formation [74,75], Girk4 knock-out mice has exhibited impaired performance in spatial learning and memory tests [75]. It is plausible that qPCR allowed us to find Girk4 transcript modulation by Aβ in hippocampal slices whereas histological techniques are not able to detect these subtle changes, as occurs in other nervous tissues with other potassium channels [38]. Thus, our results show a new reliable method to detect changes in Girk4 gene expression which may explain the impairment of hippocampal networks [75].

In summary, our data [16] suggest that Aβ could interfere with GIRK channel functioning acutely by a mechanism non described yet (e.g. altering channel relationship with lipid membrane or acting directly on the channel). This acute effect could be linked to changes in the gene expression of the channel that will reinforce the acute effect (changing channel expression or turnover) and may explain long-term deficits found in transgenic mice models of AD. However, the hypothesis of two independent mechanisms (acute and at the mRNA level) cannot be ruled out.

On the other hand, our results have shown that Aβ did not significantly modulate M1 muscarinic mRNA levels. Among different muscarinic receptors, M1 subtype has been widely related with AD [76–78]. However it has been reported that Aβ has no influence on M1 muscarinic receptors or gene expression but on the receptor/G-protein interaction [79]. KCNQ channels are the effectors of muscarinic receptors. KCNQ family comprises five members, KCNQ1–5, encoded by Kcnq1–5 genes [80]. In particular, it has been reported that KCNQ2–KCNQ3 heteromers [81], KCNQ4 [82], and KCNQ5 [83], participate in the maintenance of M-type K currents and play a crucial role in the regulation of neuronal excitability [84]. The ‘classical’ M-channel is composed of KCNQ2–KCNQ3 heteromers [81,84]. mRNA levels of both subunits are found to be early down-regulated by Aβ in the hippocampus in our study. Consistent with our findings regarding Kcnq2–3 subunits alteration, it has been recently shown that decrease in M-type K currents in medial septal area neurons may be an integral part of AD pathophysiology [27], explaining why M-type K current blockers fail to improve cognition in AD clinical trials [85]. It has also been reported that Kcnq2 gene is down-regulated by Aβ in
the hippocampus [15] and, in this conditions, M-type K current reduction would rapidly increase the excitability of hippocampal principal and GABAergic interneurons, impairing rhythmicity and synchronic activities [15,27]. At 120 minutes Aβ did not induce significant differences in Kcnq2 gene expression, suggesting some kind of compensatory response to restore the pre-Aβ incubation status as also occurs with Aβ long term effects [15,27]. Finally, it has recently been demonstrated that KCNQ5 controls excitability and function of hippocampal networks through modulation of synaptic inhibition [86]. However, in our experimental model its mRNA expression levels were found unchanged suggesting that further research is needed in this interesting direction but for now, KCNQ5 may not be linked to AD physiopathology.

Conclusions

Based on an objective standardized and validated analysis method we show the modulation of mRNA expression by Aβ_{25–35} in incubated hippocampal rat slices. In addition to the reported modulation of hippocampal glutamatergic neurotransmission by Aβ, we provided evidence of two targets for Aβ action at the molecular level that participate in controlling neuronal excitability and have recently been related with AD, KCNQ [15,27] and GirK [16] channels. Both potassium conductances have been shown to be decreased by Aβ, which contributes to the hyperexcitability and network dysfunction that underlie early stages of AD [1,2]. Our data show changes in mRNA expression of KCNQ and GirK subunits suggesting one potential Aβ mechanism at the transcriptional level that could have functional consequences such as increased network excitability. The presence of seizures and epileptiform activity in AD subjects support the hypothesis that aberrant network activity contributes causally to synaptic and cognitive deficits [13] and that a reduction in excitability with enhanced rhythmicity may be a more promising therapeutic approach in AD [1,3,14,27,87,88]. Thus, antiepileptic drugs such as KCNQ openers [89] or GirK activators [66,67,90] might ameliorate those deficits although no clinical evidence is still available [4].

Supporting Information

S1 Table. Details and primers of target and reference genes.
(XLSX)

Acknowledgments

We thank Drs. M. Martin and J.L. Albasanz (Neurochemistry Group of Ciudad Real) for their enlightening comments and technical help, Drs. A. Soler and F. Vives (UGR) for their support in the beginning of this work, and Drs. D. Vega-Avelaira and M. Nava-Mesa for their critical reading of the manuscript.

Author Contributions

Conceived and designed the experiments: LJD JDNL JMC. Performed the experiments: JMC LJD JDNL. Analyzed the data: JMC LJD. Contributed reagents/materials/analysis tools: JDNL LJD JY. Wrote the paper: JDNL LJD.

References

1. Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2: a006338. doi: 10.1101/cshperspect.a006338; a006338 [pii]. PMID: 22762015

2. Palop JJ, Mucke L (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13: 812–818. doi: 10.1038/nn.2583 PMID: 20581818
3. Palop JJ, Mucke L (2010) Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: two faces of the same coin? Neuromolecular Med 12: 48–55. doi: 10.1007/s12017-009-8097-7 PMID: 19838821

4. Nava-Mesa MO, Jimenez-Diaz L, Yajeya J, Navarro-Lopez JD (2014) GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease. Front Cell Neurosci 8: 167. doi: 10.3389/fncel.2014.00167 PMID: 24987334

5. Amaral DG, Lavenex P (2007) Hippocampal Neuroanatomy. In: Andersen P, Morris R, Amaral DG, Bliss T, O'Keefe J, editors. The Hippocampus Book. New York: Oxford University Press.

6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadian EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939–944. PMID: 6610841

7. Swanberg MM, Trachtenberg RE, Mohs R, Thal LJ, Cummings JL (2004) Executive dysfunction in Alzheimer disease. Arch Neurol 61: 556–560. doi: 10.1001/archneur.61.4.556; 61/4/556 [pii]. PMID: 15096405

8. Colom LV (2006) Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease. J Neurochem 96: 609–623. PMID: 16405497

9. Fitzjohn SM, Doherty AJ, Collingridge GL (2008) The use of the hippocampal slice preparation in the study of Alzheimer's disease. Eur J Pharmacol 585: 50–59. S0014-2999(08)00218-5 [pii]; doi: 10.1016/j.ejphar.2008.02.077 PMID: 18432444

10. Nisticò R, Pignatelli M, Piccinin S, Mercuri NB, Collingridge G (2012) Targeting synaptic dysfunction in Alzheimer's disease therapy. Mol Neurobiol 46: 572–587. doi: 10.1007/s12035-012-8324-3 PMID: 22914888

11. Seabrook GR, Rosahl TW (1999) Transgenic animals relevant to Alzheimer's disease. Neuropharmacology 38: 1–17. S0028390898001701 [pii]. PMID: 10193895

12. Noebels J (2011) A perfect storm: Converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia 52 Suppl 1: 39–46. doi: 10.1111/j.1528-1167.2010.02909.x PMID: 21214538

13. Palop JJ, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66: 435–440. 2009.15 PMID: 19204149

14. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K et al. (2012) Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149: 708–721. S0092-8674(12)00284-X [pii]; doi:10.1016/j.cell.2012.02.046 PMID: 22541439

15. Duran-Gonzalez J, Micha ED, Elorzba B, Perez-Cordova MG, Pacheco-Otalora LF, Touhami A et al. (2013) Amyloid beta peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system. Neurobiol Aging 34: 2071–2076. S0197-4580(13)0067-5 [pii]; doi:10.1016/j.neurobiolaging.2013.02.005 PMID: 23473707

16. Nava-Mesa MO, Jimenez-Diaz L, Yajeya J, Navarro-Lopez JD (2013) Amyloid-beta induces synaptic dysfunction through G protein-gated inwardly rectifying potassium channels in the fimbria-CA3 hippocampal synapse. Front Cell Neurosci 7: 117. doi:10.3389/fncel.2013.00117 PMID: 23898239

17. Hall AM, Throesch BT, Buckingham SC, Markwardt SJ, Peng Y, Wang Q et al. (2015) Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease. J Neurosci 35: 6221–6230. 35/15/6221 [pii]; doi:10.1523/JNEUROSCI.2552-14.2015 PMID: 25878292

18. Sperling RA, LaViolette PS, O’Keefe K, O’Brien J, Rentz DM, Pihlajamaki M et al. (2009) Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63: 178–188. S0896-6273(09)00505-4 [pii]; doi:10.1016/j.neuron.2009.07.003 PMID: 19640477

19. Kerrigan TL, Randall AD (2013) A new player in the “synaptopathy” of Alzheimer’s disease—arc/arg 3.1. Front Neurol 4: 9. doi: 10.3389/fneur.2013.00009 PMID: 23407382

20. Albasanz JL, Dalfo E, Ferrer I, Martin M (2005) Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. Neurobiol Dis 20: 685–693. S0969-9616(05)00137-3 [pii]; doi:10.1016/j.nbd.2005.05.001 PMID: 15949941

21. Hynd MR, Scott HL, Dodd PR (2001) Glutamate(NMDA) receptor NR1 subunit mRNA expression in Alzheimer's disease. J Neurochem 78: 175–182. PMID: 11432984

22. Ashenafi S, Fuente A, Criado JM, Riolobos AS, Heredia M, Yajeya J (2005) Beta-Amyloid peptide25-35 depresses excitatory synaptic transmission in the rat basolateral amygdala "in vitro". Neurobiol Aging 26: 419–428. PMID: 15653170

23. Navarro-Lopez JD, Alvarado JC, Marquez-Ruiz J, Escudero M, Delgado-Garcia JM, Yajeya J (2004) A cholinergic synaptically triggered event participates in the generation of persistent activity necessary
for eye fixation. J Neurosci 24: 5109–5118. doi: 10.1523/JNEUROSCI.0235-04.2004; 24/22/5109 [pii]. PMID: 15175380

24. Milucci L, Ghezzi L, Bernardini G, Santucci A (2010) Conformations and biological activities of amyloid beta peptide 25–35. Curr Protein Pept Sci 11: 54–67. CPPS-26 [pii]. PMID: 20201807

25. Klementiev B, Novikova T, Novitskaya V, Walmad PS, Dmytriyeva O, Pakkenberg B et al. (2007) A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35. Neuroscience 145: 209–224. S0306-4522(06)01656-3 [pii]; doi: 10.1016/neuroscience.2006.11.060 PMID: 17223274

26. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA (2001) Different mechanisms of oxidative stress and neurotoxicity for Alzheimer’s A beta(1–42) and A beta(25–35). J Am Chem Soc 123: 5625–5631. ja010452r [pii]. PMID: 11403592

27. Leao RN, Colom LV, Borgius L, Kiehn O, Fisahn A (2012) Medial septal dysfunction by Abeta-induced KCNQ channel-block in glutamaticeric neurons. Neurobiol Aging 33: 2046–2061. S0197-4580(11)00297-1 [pii]; doi: 10.1016/j.neurobiolaging.2011.07.013 PMID: 21907458

28. Peña F, Ordaz B, Balleza-Tapia H, Bernal-Pedraza R, Marquez-Ramos A, Carmona-Aparicio L et al. (2010) Beta-amyloid protein (25–35) disrupts hippocampal network activity: role of Fyn-kinase. Hippocampus 20: 78–96. doi: 10.1002/hipo.20592 PMID: 19294646

29. Santos-Torres J, Fuente A, Criado JM, Riobobos AS, Heredia M, Yajeya J (2007) Glutamaticeric synaptic depression by synthetic amyloid beta-peptide in the medial septum. J Neurosci Res 85: 634–648. PMID: 17171717

30. Chang Z, Luo Y, Zhang Y, Wei G (2011) Interactions of Abeta25-35 beta-barrel-like oligomers with anionic lipid bilayer and resulting membrane leakage: an all-atom molecular dynamics study. J Phys Chem B 115: 1165–1174. doi: 10.1021/jp107558e PMID: 21192698

31. Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL et al. (2010) Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer’s Disease and Down syndrome. Proc Natl Acad Sci U S A 107: 6538–6543. 0912451107 [pii]; doi: 10.1073/pnas.0912451107 PMID: 20308552

32. Guzowski JF, Setlow B, Wagner EK, McGaugh JL (2001) Experience-dependent gene expression in the rat hippocampus after spatial learning: a comparison of the immediate-early genes Arc, c-fos, and zif268. J Neurosci 21: 5089–5098. 21/14/5089 [pii]. PMID: 11438584

33. Parra-Damas A, Valero J, Chen M, Espana J, Martin E, Ferrer I et al. (2014) Crtc1 activates a transcriptional program deregulated at early Alzheimer’s disease-related stages. J Neurosci 34: 5776–5787. 34/17/5776 [pii]; doi: 10.1523/JNEUROSCI.5288-13.2014 PMID: 24760838

34. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M et al. (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7: 3. 1471-2199-7-3 [pii]; doi: 10.1186/1471-2199-7-3 PMID: 16448564

35. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611–622. clinchem.2008.112797 [pii]; doi: 10.1373/clinchem.2008.112797 PMID: 19246619

36. Lefever S, Hellemans J, Pattyn F, Przybylski DR, Taylor C, Geurts R et al. (2009) RDML: structured language and reporting guidelines for real-time quantitative PCR data. Nucleic Acids Res 37: 2065–2069. gkp056 [pii]; doi: 10.1093/nar/gkp056 PMID: 19223324

37. Jimenez-Diaz L, Nava-Mesa MO, Heredia M, Riobobos AS, Gomez-Alvarez M, Criado JM et al. (2011) Embryonic amygdalar transplants in adult rats with motor cortex lesions: a molecular and electrophysiological analysis. Front Neurol 2: 59. doi: 10.3389/fneur.2011.00059 PMID: 21954393

38. Navarro-Lopez J, Jimenez-Diaz L, Gerantos SM, Ashmore JF (2009) Electrophysiological and molecular analysis of Kv7/KCNQ potassium channels in the inferior colliculus of adult guinea pig. J Mol Neurosci 37: 263–268. doi: 10.1007/s12031-008-9130-2 PMID: 18663605

39. Jacob F, Guertler R, Naim S, Nixdorf S, Fedier A, Hacker NF et al. (2013) Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines. PLoS One 8: e59180. doi: 10.1371/journal.pone.0059180; PONE-D-12-39531 [pii]. PMID: 23554992

40. Langnaese K, John R, Schweizer H, Ebmeyer U, Keilhoff G (2008) Selection of reference genes for quantitative real-time PCR in a rat asphyxial cardiac arrest model. BMC Mol Biol 9: 53. 1471-2199-9-53 [pii]; doi: 10.1186/1471-2199-9-53 PMID: 18505597

41. Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64: 5245–5250. doi: 10.1158/0008-5472. CAN-04-0496; 64/15/5245 [pii]. PMID: 15289330
42. Pfaffl MW, Tichopad A, Prögomet C, Neuvians TP (2004) Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper—Excel-based tool using pair-wise correlations. Biootechnol Lett 26: 509–515. PMID: 15127993

43. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL et al. (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24: 10191–10200. PMID: 15537891

44. Fleige S, Wall V, Huch S, Prögomet C, Sehm J, Pfaffl MW (2006) Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biootechnol Lett 28: 1601–1613. doi: 10.1007/s10529-006-9127-2 PMID: 16900335

45. Bonefeld BE, Elfving B, Wegener G (2008) Reference genes for normalization: a study of rat brain tissue. Synapse 62: 302–309. doi: 10.1002/syn.20496 PMID: 18241047

46. Butte AJ, Dzau VJ, Glueck SB (2001) Further defining housekeeping, or "maintenance," genes Focus on "A compendium of gene expression in normal human tissues". Physiol Genomics 7: 95–96. 7/2/95 [pii]. PMID: 11773595

47. Everaert BR, Boulet GA, Timmermans JP, Vrints CJ (2011) Importance of suitable reference gene selection for quantitative real-time PCR: special reference to mouse myocardial infarction studies. PLoS One 6: e23793. doi: 10.1371/journal.pone.0023793; PONE-D-11-00818 [pii]. PMID:21858224

48. Seifert W (1983) Neurobiology of the Hippocampus. London: Academic Press.

49. Andersen P, Morris R, Amaral DG, Bliss T, O'Keefe J (2007) Historical Perspective: Proposed Functions, Biological Characteristics, and Neurobiological Models of the Hippocampus. In: Andersen P, Morris R, Amaral DG, Bliss T, O’ Keefe J, editors. The Hippocampus Book. New York: Oxford University Press.

50. Cho S, Wood A, Bowby MR (2007) Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr Neuropharmacol 5: 19–33. PMID: 18615151

51. Sebollela A, Freitas-Correa L, Oliveira FF, Saraiva LM, Martins SM et al. (2012) Amyloid-beta oligomers induce differential gene expression in adult human brain slices. J Biol Chem 287: 7436–7445. M111.298471 [pii]. doi: 10.1074/jbc.M111.298471 PMID: 22235132

52. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N et al. (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55: 697–711. PMID: 17785178

53. Miñano-Molina AJ, Espana J, Martín E, Barreda-Zahonero B, Fado R, Sole M et al. (2011) Soluble oligomers of amyloid-beta peptide disrupt membrane trafficking of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synapse dysfunction. J Biol Chem 286: 27311–27321. M111.227504 [pii]. doi: 10.1074/jbc.M111.227504 PMID: 21665950

54. Gaisler-Salomon I, Kravitz E, Feiler Y, Safran M, Biegon A, Amariglio N et al. (2014) Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease. Neurobiol Aging 35: 1785–1791. S0197-4580(14)00224-3 [pii]; doi:10.1016/j.neurobiolaging.2014.02.018 PMID: 24679603

55. Williams C, Mehrian SR, Wu Y, Hsu YH, Sitzer T, Spann B et al. (2009) Transcriptome analysis of synaptoneurosomes identifies neuroplasticity genes overexpressed in incipient Alzheimer's disease. PLoS One 4: e4936. doi: 10.1371/journal.pone.0004936 PMID: 19295912

56. Mota SI, Ferreira IL, Rego AC (2014) Dysfunctional synapse in Alzheimer's disease—A focus on NMDA receptors. Neuropharmacology 76 Pt A: 16–26. S0028-3908(13)00378-X [pii]; doi:10.1016/j.neuropharmacology.2013.08.013 PMID: 23973316

57. Parameshwaran K, Dhanasekaran M, Suppiramaniam V (2008) Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol 210: 7–13. S0014-4886(07)00391-3 [pii]; doi:10.1016/j.expneurol.2007.10.008 PMID: 18053990

58. X1 YD, Ding J, Han J, Zhang DD, Liu JM, Feng LL et al. (2015) The Effect of Soybean Isoflavone on the Dysregulation of NMDA Receptor Signaling Pathway Induced by beta-Amyloid Peptides 1–42 in Rats. Cell Mol Neurobiol. doi: 10.1007/s10571-014-0151-9

59. Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N et al. (2007) Alterations in neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neurochem Int 45: 583–595. doi: 10.1016/j.neuint.2007.08.013 PMID: 17361039

60. Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45: 583–595. doi: 10.1016/j.neuint.2004.03.007; S0197018604000555 [pii]; PMID: 15234100

61. Mishizen-Eberz AJ, Rissman RA, Carter TL,ikonovmov MD, Wolfe BB, Armstrong DM (2004) Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Dis 15: 80–92. S0969996103001918 [pii]; PMID: 14751773
62. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A et al. (2012) Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15: 1227–1235. PMID: 22820466

63. Um JW, Strittmatter SM (2013) Amyloid-beta induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion 7: 37–41. PMID: 22987042

64. Pinheiro PS, Mulle C (2008) Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat Rev Neurosci 9: 423–436. PMID: 18464791

65. Kumar A, Dhall DK, Mishra PS (2015) Therapeutic potential of mGluR5 targeting in Alzheimer's disease. Front Neurosci 9: 215. doi:10.3389/fnins.2015.00215 PMID: 26106290

66. Luscher C, Slesinger PA (2010) Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nat Rev Neurosci 11: 301–315. PMID: 20389305

67. Lujan R, Marron Fernandez de Velasco E, Aguado C, Wickman K (2014) New insights into the therapeutic potential of GIRK channels. Trends Neurosci 37: 20–29. PMID: 24268819

68. Cooper A, Grigoryan G, Guy-David L, Tsoory MM, Chen A, Reuveny E (2012) Trisomy of the G protein-coupled K+ channel gene, Kcnj6, affects reward mechanisms, cognitive functions, and synaptic plasticity in mice. Proc Natl Acad Sci U S A 109: 2642–2647. PMID: 22308328

69. Lott IT, Head E (2005) Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging 26: 383–389. PMID: 15639317

70. Moncaster JA, Pineda R, Moir RD, Lu S, Burton MA, Ghosh JG et al. (2010) Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One 5: e10659. doi:10.1371/journal.pone.0010659 PMID: 20502642

71. Karschin C, Dissmann E, Stuhmer W, Karschin A (1996) IRK(1–3) and GIRK(1–4) inwardly rectifying K+ channel mRNAs are differentially expressed in the adult rat brain. J Neurosci 16: 3559–3570. PMID: 8642402

72. Spauschus A, Lentes KU, Wischmeyer E, Karschin C, Karschin A (1996) A G-protein-activated inwardly rectifying K+ channel (GIRK4) from human hippocampus associates with other GIRK channels. J Neurosci 16: 930–938. PMID: 8558261

73. Perry CA, Pravetoni M, Teske JA, Aguado C, Erickson DJ, Medrano JF et al. (2008) Predisposition to late-onset obesity in GIRK4 knockout mice. Proc Natl Acad Sci U S A 105: 8148–8153. PMID: 1803261105

74. Murer G, Adelbrecht C, Lauterjung I, Lesage F, Lazdunski M, Agid Y et al. (1997) An immunocytochemical study on the distribution of two G-protein-gated inward rectifier potassium channels (GIRK2 and GIRK4) in the adult rat brain. Neuroscience 80: 345–357. PMID: 9284339

75. Wickman K, Karschin C, Karschin A, Picciotto MR, Clapham DE (2000) Brain localization and behavioral impact of the G-protein-gated K+ channel subunit GIRK4. J Neurosci 20: 5608–5615. PMID: 10908597

76. Caccamo A, Fisher A, LaFerla FM (2009) M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res 6: 112–117. PMID: 19355845

77. Tsang SW, Lai MK, Kirvell S, Francis PT, Esiri MM, Hope T et al. (2006) Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol Aging 27: 1216–1223. PMID: 16129514

78. Fisher A (2012) Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J Neurochem 120 Suppl 1: 22–33. PMID: 22122190

79. Janickova H, Rudavey V, Zimnicky P, Jakubik J, Tanila H, El-Fakahany EE et al. (2013) Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid beta(1–42). Neuropsychopharmacol 67: 272–283. PMID: 23206502

80. Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE et al. (2003) International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev 55: 583–586. PMID: 14657415

81. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS et al. (1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282: 1890–1893. PMID: 9836639
82. Kubisch C, Schroeder BC, Friedrich T, Lutjohann B, El-Amraoui A, Marlin S et al. (1999) KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell 96: 437–446. PMID: 10025409

83. Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ (2000) KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem 275: 24089–24095. PMID: 10816588

84. Delmas P, Brown DA (2005) Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 6: 850–862. PMID: 16261179

85. Rockwood K, Beattie BL, Eastwood MR, Feldman H, Mohr E, Pryse-Phillips W et al. (1997) A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Can J Neurol Sci 24: 140–145. PMID: 9164692

86. Fidzinski P, Korotkova T, Heidenreich M, Maier N, Schuetze S, Kobler O et al. (2015) KCNQ5 K(+) channels control hippocampal synaptic inhibition and fast network oscillations. Nat Commun 6: 6254. ncomms7254 [pii]; doi:10.1038/ncomms7254 PMID: 25649132

87. Peters HC, Hu H, Pongs O, Storm JF, Isbrandt D (2005) Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior. Nat Neurosci 8: 51–60. nn1375 [pii]; PMID: 15608631

88. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148: 1204–1222. S0092-8674(12)00278-4 [pii]; doi:10.1016/j.cell.2012.02.040 PMID: 22424230

89. Linley JE, Pettinger L, Huang D, Gamper N (2012) M channel enhancers and physiological M channel block. J Physiol 590: 793–807. jphysiol.2011.223404 [pii]; doi:10.1113/jphysiol.2011.223404 PMID: 22155935

90. Kaufmann K, Romaine I, Days E, Pascual C, Malik A, Yang L et al. (2013) ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice. ACS Chem Neurosci 4: 1278–1286. doi: 10.1021/cn400062a PMID: 23730969